Litocar Injection contains Levo-carnitine 1000 mg, an essential nutrient involved in the transport of long-chain fatty acids into the mitochondria for energy production. It is primarily indicated for the treatment of carnitine deficiency, which may be congenital or acquired due to metabolic disorders, dialysis, or certain medications. Levo-carnitine plays a critical role in cellular energy metabolism, particularly in cardiac and skeletal muscle tissues, and its supplementation helps improve muscle function and reduce symptoms of fatigue and weakness. Litocar Injection is administered intramuscularly or intravenously under medical supervision, ensuring rapid bioavailability and effective plasma concentrations. This formulation is especially beneficial in patients with primary or secondary carnitine deficiency, including those with chronic renal failure, hepatic encephalopathy, or certain inborn errors of metabolism. Adverse effects are generally mild and may include gastrointestinal disturbances, injection site reactions, or allergic responses. Caution is advised in patients with hypothyroidism or seizure disorders. Litocar Injection should be used according to prescribed dosages and under the guidance of a healthcare professional to optimize therapeutic outcomes and minimize risks. Regular monitoring of carnitine levels and clinical response is recommended during treatment.